Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC plus atezolizumab and bevacizumab for unresectable advanced hepatocellular carcinoma
jRCTs061210065Completed
- Sponsor
- Nippon Kayaku Co., Ltd.
- Start
- Jan 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of atezolizumab, bevacizumab and cisplatin in hepatocellular carcinoma (HCC) (2 arms), sponsored by Nippon Kayaku Co., Ltd. Primary endpoint: Response rate by mRECIST. Started Jan 2022; status: completed.
02
Drugs
atezolizumabbevacizumabcisplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs061210065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061210065.